Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Kojima, T.
Right arrow Articles by Akaza, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kojima, T.
Right arrow Articles by Akaza, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology 34:137-141 (2004)
© 2004 Foundation for Promotion of Cancer Research

Weekly Administration of Docetaxel in Patients with Hormone-refractory Prostate Cancer: a Pilot Study on Japanese Patients

Takahiro Kojima, Toru Shimazui, Mizuki Onozawa, Sadamu Tsukamoto, Shiro Hinotsu, Naoto Miyanaga, Kazunori Hattori, Koji Kawai and Hideyuki Akaza+

Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba City, Ibaraki, Japan

Objective: Although treatment of hormone-refractory prostate cancer (HRPC) is difficult, a single-agent weekly dose of docetaxel has been reported as a promising regimen for patients with HRPC. The purpose of this study was the investigation of the efficacy of docetaxel for Japanese patients with HRPC.

Methods: Ten patients with HRPC were treated with weekly docetaxel at Tsukuba University Hospital and were evaluated for the responses with respect to serum prostate-specific antigen (PSA), tumor size and survival. Considering the ethnic balance, the dose of docetaxel was reduced to 30 mg/m2 weekly compared with 36 mg/m2 in the study reported previously.

Results: A biochemical response (>50% decrease in PSA) was observed in five patients (56%; 5/9) with an average time to progression of 4.5 months. In two partial responders as determined by PSA, respective metastatic lesions in bone and soft tissue were also improved. The estimated median survival duration was 6 months. Most of these responses were accompanied by a significant reduction in the requirement for analgesic agents. No severe toxicity of this regimen was observed, except for gastric ulcer in one patient who was excluded from the evaluation.

Conclusions: Weekly administration of docetaxel as a single agent was associated with a high rate of PSA reduction. This treatment is feasible for patients with HRPC, even those who have a poor performance status and extensive prior treatments.

+ For reprints and all correspondence: Takahiro Kojima, Department of Urology, Tsukuba University Hospital, 2–1–1 Amakubo, Tsukuba City, Ibaraki 305-8576, Japan. E-mail: tkojima-jua{at}umin.ac.jp


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
S. Naito, T. Tsukamoto, H. Koga, T. Harabayashi, Y. Sumiyoshi, S. Hoshi, and H. Akaza
Docetaxel Plus Prednisolone for the Treatment of Metastatic Hormone-refractory Prostate Cancer: A Multicenter Phase II Trial in Japan
Jpn. J. Clin. Oncol., May 1, 2008; 38(5): 365 - 372.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
T. Shimazui, K. Kawai, N. Miyanaga, T. Kojima, N. Sekido, S. Hinotsu, T. Oikawa, A. Joraku, and H. Akaza
Three-weekly Docetaxel with Prednisone is Feasible for Japanese Patients with Hormone-refractory Prostate Cancer: A Retrospective Comparative Study with Weekly Docetaxel Alone
Jpn. J. Clin. Oncol., August 2, 2007; (2007) hym071v1.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.